All compounds
Fat lossGrowth Hormone
Tesamorelin
Visceral Fat & GHRH Analog
Typical Dose
1–2 mg
Route
Injectable
Variants
10mg · 20mg
Overview
What is Tesamorelin?
Tesamorelin is a stabilized GHRH analog clinically studied to reduce visceral adipose tissue while supporting cognition and lipid profile.
Mechanism of Action
Stimulates GHRH receptors on the pituitary, producing GH and IGF-1 elevation with a strong visceral-fat lipolytic effect.
Key Benefits
- Visceral fat reduction
- Improved lipid profile
- Cognitive support
- Lean mass preservation
Research Indications
Visceral fat reductionMost Effective
HIV-associated lipodystrophyMost Effective
Cognitive function (older adults)Effective
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Conservative | 1 mg | 1x daily | Subcutaneous (PM) |
| Standard starting dose | 1.4 mg | 1x daily | Subcutaneous |
| Typical maintenance | 2 mg | 1x daily 5/7 | Subcutaneous |
| Maximum | 2 mg | 1x daily | Subcutaneous |
Peptide Interactions
AOD-9604
Retatrutide
Insulin
Side Effects & Safety
Common Side Effects
- Injection-site reaction
- Joint stiffness
- Mild edema
Safety Guidelines
- For laboratory research use only — not for human consumption
- Store reconstituted vials at 2–8°C, use within 30 days
- Rotate injection sites to avoid local irritation
- Discontinue and consult a clinician if adverse reactions occur
Quality Indicators
- ≥95% purity verified by HPLC
- Third-party tested for sterility
- Lyophilized in sealed multi-dose vial
- Bacteriostatic water reconstitution
- Refrigerated cold-chain shipping
What to Expect
- 1Week 1–2Sleep and recovery improvements
- 2Week 3–6Visceral fat reduction begins
- 3Week 7–12Visible waist and lipid improvements
Need a different compound?
Browse all peptides